Matrix Capital Management Company LP lowered its position in Adaptimmune Therapeutics plc (NASDAQ:ADAP - Free Report) by 3.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,681,515 shares of the biotechnology company's stock after selling 1,292,670 shares during the period. Adaptimmune Therapeutics makes up about 1.7% of Matrix Capital Management Company LP's investment portfolio, making the stock its 6th biggest position. Matrix Capital Management Company LP owned approximately 14.73% of Adaptimmune Therapeutics worth $35,813,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics in the third quarter worth about $33,000. Vontobel Holding Ltd. grew its position in Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 30,000 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter valued at $95,000. FMR LLC boosted its stake in shares of Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company's stock valued at $1,655,000 after buying an additional 50,419 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock valued at $1,742,000 after purchasing an additional 394,566 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on ADAP. HC Wainwright cut their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a "buy" rating for the company in a research report on Thursday, November 14th. Guggenheim decreased their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. StockNews.com lowered shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 14th. Finally, Mizuho cut their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an "outperform" rating on the stock in a report on Wednesday, November 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $2.79.
Read Our Latest Research Report on Adaptimmune Therapeutics
Adaptimmune Therapeutics Stock Performance
Adaptimmune Therapeutics stock traded up $0.00 during midday trading on Wednesday, hitting $0.70. The company's stock had a trading volume of 2,563,251 shares, compared to its average volume of 1,725,840. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics plc has a 1-year low of $0.43 and a 1-year high of $2.05. The company has a market cap of $179.12 million, a price-to-earnings ratio of -3.15 and a beta of 2.18. The company has a 50-day moving average price of $0.79 and a two-hundred day moving average price of $0.99.
Adaptimmune Therapeutics Profile
(
Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
See Also
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
